Rev­o­lu­tion Med shoots for $100M+ IPO — and di­vulges some se­crets about that Warp Dri­ve buy­out

Biotech in­vestors who like to wa­ger on the race to the front of the KRAS mar­ket now have a new team to con­sid­er.

Rev­o­lu­tion Med­i­cines, which ex­tend­ed its reach on RAS with a deal to ac­quire Warp Dri­ve Bio about 18 months ago, filed their S-1 in search of $100 mil­lion-plus. And they gave up a few se­crets in the process.

The main clin­i­cal claim to fame that Rev­o­lu­tion has cen­tered on is the SHP2 in­hibitor RMC-4630, part­nered with Sanofi back in the sum­mer of 2018 — just af­ter John Reed was named the in­com­ing R&D chief. We al­ready knew that the phar­ma gi­ant hand­ed over $50 mil­lion in cash plus a com­mit­ment of hun­dreds of mil­lions more to align it­self with Rev­o­lu­tion as it makes a fresh for­ay in­to on­col­o­gy. Now we know that Sanofi is al­so foot­ing 80% of Rev­o­lu­tion’s R&D bill on the pro­gram, while set­ting up a smor­gas­bord of $235 mil­lion in de­vel­op­ment mile­stones and $285 mil­lion in com­mer­cial bonus­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.